Scarica l'app Stockscreener
9.216
3.48%
0.316
Precedente Chiudi:
$8.90
Aprire:
$8.9
Volume 24 ore:
1.46M
Relative Volume:
1.26
Capitalizzazione di mercato:
$429.90M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-3.4647
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+9.64%
1M Prestazione:
+35.24%
6M Prestazione:
+250.19%
1 anno Prestazione:
+0.44%
Intervallo 1D:
$8.50
$9.22
Intervallo di 1 settimana:
$8.1101
$10.03
Portata 52W:
$2.235
$10.03
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.205 | 415.65M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.45 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.96 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study - MarketScreener
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTrade Ideas & Precise Buy Zone Tips - newser.com
Is it too late to sell 4D Molecular Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
4D Molecular (FDMT) Gains $11M Support for Cystic Fibrosis Treat - GuruFocus
Is it time to cut losses on 4D Molecular Therapeutics Inc.Trade Signal Summary & Risk Managed Investment Strategies - newser.com
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation - Stock Titan
When is the best time to exit 4D Molecular Therapeutics Inc.Rate Hike & Risk Managed Investment Entry Signals - newser.com
Momentum divergence signals in 4D Molecular Therapeutics Inc. chart2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Will 4D Molecular Therapeutics Inc. see short term momentumJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
4D Molecular Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Access Powerful Market Insights - earlytimes.in
Real time alert setup for 4D Molecular Therapeutics Inc. performancePortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
What drives 4D Molecular Therapeutics Inc stock priceTrade Execution Strategies & Free Stock Chart Pattern Guides - earlytimes.in
Statistical indicators supporting 4D Molecular Therapeutics Inc.’s strength2025 Valuation Update & Weekly High Return Opportunities - newser.com
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance
How 4D Molecular Therapeutics Inc. stock responds to policy changesJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
What MACD signals say about 4D Molecular Therapeutics Inc.2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
What the charts say about 4D Molecular Therapeutics Inc. todayProduct Launch & Accurate Buy Signal Alerts - newser.com
4D Molecular Therapeutics says on Sept 30, appointed Ashoo Gupta as principal financial officerSEC filing - MarketScreener
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT) - Seeking Alpha
Can momentum traders help lift 4D Molecular Therapeutics Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
What analysts say about 4D Molecular Therapeutics Inc stockMarket Insider Reports & Free Explosive Wealth Accumulation - earlytimes.in
Is 4D Molecular Therapeutics Inc. stock reversal real or fakeWeekly Stock Summary & Consistent Growth Equity Picks - newser.com
News impact scoring models applied to 4D Molecular Therapeutics Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 By Investing.com - Investing.com Canada
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 - Investing.com India
4D Molecular Therapeutics Inc. stock daily chart insightsWeekly Trend Report & Verified Technical Trade Signals - newser.com
Is 4D Molecular Therapeutics Inc. stock bottoming outStop Loss & Accurate Entry/Exit Alerts - newser.com
Custom strategy builders for tracking 4D Molecular Therapeutics Inc.2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):